Complementary Cancer Treatment Research Articles

Anti-proliferative effect of 8α-tigloyloxyhirsutinolide-13-O-acetate (8αTGH) isolated from Vernonia cinerea on oral squamous cell carcinoma through inhibition of STAT3 and STAT2 phosphorylation

BackgroundThe high mortality rate of oral cancers has stimulated the search for effective herbal medicines and their pharmacological targets. Vernonia cinerea, a perennial tropical herb, is wildly used as a traditional folk medicine for treatment of intestinal diseases and various skin diseases in addition to possessing anti-cancer activity. However, the effect of 8α-tigloyloxyhirsutinolide-13-O-acetate (8αTGH) as a major sesquiterpene lactone compound found in V. cinerea and the underlying mechanism of its action on oral cancer cells remains unknown. PurposeTo investigate the anti-cancer activity of 8αTGH extracted from V. cinerea and the underlying mechanism of its action in oral cancer cells. MethodsThe anti-proliferative effect of 8αTGH on oral squamous cell carcinoma (HSC4) and lung carcinoma (A549) was determined using the SRB colorimetric method. The molecular mechanism of 8αTGH was explored using kinase inhibitors, followed by Western blotting or RT-qPCR. Flow cytometry and Western blotting were used to assess cell cycle arrest. Results8αTGH inhibited cancer cell growth more effectively on HSC4 than A549 and was much less effective on tested normal oral cells. 8αTGH inhibited STAT3 phosphorylation on both cancer cells. Notably, 8αTGH was able to suppress the constantly activated STAT2 found only in HSC4. The STAT2 inhibition by 8αTGH consequently caused down-regulation of ISG15 and ISG15 conjugates. As a result, decreased expression of CDK1/2 and Cyclin B1 was detected leading to G2/M cell cycle arrest. Conclusion8αTGH isolated from V. cinerea preferentially inhibits the proliferation of oral cancer cells by causing G2/M cell cycle arrest via inhibition of both STAT3 and STAT2 phosphorylation. The results provide molecular bases for developing 8αTGH as a drug candidate or a complementary treatment of oral cancer.

English

Mistletoes are hemi-parasitic plants widely distributed around the world, used in folk medicine to treat many diseases including diabetes, hypertension, menopausal syndrome and as complementary or adjuvant treatment for cancer. The objective of the present work was the evaluation of oestrogenic activity of hydromethanolic extract of mistletoe Struthanthus venetus dried leaves (StvHME), to evaluate its potential benefits in menopause and breast cancer, which have not been reported so far. Uterotrophic activity was evaluated in immature female CD1 mice, administering StvHME (10, 100 and 500 mg/kg) for three consecutive days compared to the natural hormone 17β-oestradiol (E2, 10 μg/kg). Comparison of the MCF-7 positive oestrogen receptor human breast adenocarcinoma cell proliferation in the presence of StvHME (0.5, 5 and 50 μg/ml) or E2 (10-12-10-10M) related to untreated control cells was assessed using MTT cell viability assay. StvHME, produced biphasic effects in mice uteri; low doses (10 mg/kg) decreased uterine weight (15-38%; p<0.05), while a higher dose (500 mg/kg) increased uterine weight (28-36%; p<0.05). StvHME concentrations tested inhibited MCF-7 cell proliferation, contrasting with E2 which increased it. StvHME (50 μg/ml) antagonized the proliferative response to E2 (10-12 to 10-10 M) behaving as an anti-oestrogen. The antiproliferative response of StvHME (50 μg/ml) showed synergism with the oestrogen antagonists Tamoxifen and Fulvestrant (ICI 182,780). Our results suggest the presence of oestrogenic and anti-oestrogenic components in the StvHME that could be acting through the oestrogen ERα and ERβ receptors. Therefore, StvHME has potential utility as a complementary therapy for breast cancer. Key words: mistletoe, Struthanthus venetus, MCF-7 cells, oestrogenicity, anti-oestrogenic, anti-cancer, menopause. &nbsp

Acetone extract of Flammulina velutipes caps: A promising source of antioxidant and anticancer agents

The high death rate associated with cancer has fuelled the search for complementary cancer treatment methods in recent times. Among the leading alternative methods is natural products which have attracted much attention due to their high body tolerance. In this study, the caps of Flammulina velutipes (commonly called Enoki), an edible mushroom, were extracted with different solvents and characterized for in vitro antioxidant and anticancer activities. The anticancer activity of the extract was studied against breast cancer cells (MCF-7 and MDA-MD-231) and normal or Vero breast cells (MCF-10a). The radical scavenging, metal reducing power, and anticancer properties of the extracts were investigated via in vitro chemical and cell-based methods. Furthermore, a phytochemical profiling process was performed on the extract fraction with the highest level of biological activities using Liquid chromatography-mass spectrometry coupled with quadrupole time of flight (LC-MS-QTof). The results showed acetone fraction of Enoki caps to exhibit more radical scavenging activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals (IC50 = 0.840 mg/mL) and hydrogen peroxide (H2O2) radicals (IC50 = 0.890 mg/mL) compared to the ethyl acetate fraction (IC50 = 0.97 mg/mL against DPPH and 1.180 mg/mL against H2O2). Additionally, acetone fraction showed a better metal reducing property in a concentration-dependent manner. The in vitro cytotoxicity study showed a preferential level of toxicity of the acetone extract to the studied cancer cell lines compared to the Vero cells. This extract showed more cytotoxicity against MCF-7 (IC50 value ranged from 17.7 µg/mL to 38.36 µg/mL) and MDA-MB-231 (IC50 value ranged from 114.5 µg/mL to 184.2 µg/mL) compared to MCF-10a (>250 µg/mL). These findings present F. velutipes caps as a potential natural source of antioxidant and anticancer agents.

Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin.

Despite new and exciting research and renewed optimism about future therapy, current statistics of survival from pancreatic cancer remains dismal. Patients seeking alternative or complementary treatments should be warned to avoid the hype and instead look to real science. A variety of relatively safe and inexpensive treatment options that have shown success in preclinical models and/or retrospective studies are currently available. Patients require their physicians to provide therapeutic guidance and assistance in obtaining and administrating these various therapies. Paricalcitol, an analog of vitamin D, has been shown by researchers at the Salk Institute for Biological Studies to break though the protective stroma surrounding tumor cells. Hydroxychloroquine has been shown to inhibit autophagy, a process by which dying cells recycle injured organelles and internal toxins to generate needed energy for survival and reproduction. Intravenous vitamin C creates a toxic accumulation of hydrogen peroxide within cancer cells, hastening their death. Metformin inhibits mitochondrial oxidative metabolism utilized by cancer stem cells. Statins inhibit not only cholesterol but also other factors in the same pathway that affect cancer cell growth, protein synthesis, and cell cycle progression. A novel formulation of curcumin may prevent resistance to chemotherapy and inhibit pancreatic cancer cell proliferation. Aspirin therapy has been shown to prevent pancreatic cancer and may be useful to prevent recurrence. These therapies are all currently available and are reviewed in this paper with emphasis on the most recent laboratory research and clinical studies.

Attitudes and knowledge about direct and indirect risks among conventional and complementary health care providers in cancer care

BackgroundMany complementary therapies offer benefits for patients with cancer. Others may be risky for patients due to negative interactions with conventional treatment and adverse effects. Therefore, cancer patients need guidance from health care providers to assess complementary modalities appropriately to receive benefits and avoid harm.MethodIn a self-administered questionnaire-based cross-sectional study, we compared knowledge and attitudes of health care providers with no training in complementary modalities to that of health care providers with training in complementary modalities about the risks for patients who combine complementary modalities with conventional treatment in cancer care. The analysis was based on responses from 466 participants.ResultsThe attitudes and knowledge about direct risk followed provider specialty. Ninety-four percent of the medical doctors, 93% of the nurses, and 87% of the providers with dual training, but 70% of the complementary therapists, believed that complementary modalities can cause adverse effects (p < 0.001). The majority of the medical doctors and nurses believed that it is risky to combine complementary and conventional cancer treatments (78% and 93%, respectively), compared to 58% of the providers with dual training and 43% of the complementary therapists (p < 0.001). Eighty-nine percent of the medical doctors and nurses believed that complementary modalities should be subjected to more scientific testing before being accepted by conventional health care providers, in contrast to 56% of the dually trained and 57% of the complementary therapists (p < 0.001). The majority of the medical doctors (61%) and nurses (55%) would have neither discouraged nor encouraged the use of complementary modalities if patients asked them for advice. Moreover, less than 1% of the complementary therapists would have discouraged the use of conventional cancer treatments. The study participants believed that the most important factor to recommend a complementary cancer modality to patients is evidence for safety.ConclusionThe health care providers in this study believed that complementary modalities are associated with direct risk and can cause adverse effects, and that it is risky to combine conventional and complementary treatments due to potential harmful interactions.

Extract from Butea monosperma inhibits β-catenin/Tcf signaling in SW480 human colon cancer cells

The colorectal cancer (CRC) is the fourth leading cause of cancer death in worldwide. It has been found that >90% of CRC is caused by aberrant activation of canonical Wnt/β-catenin signaling pathway. Continuous activation of this pathway believes to be an initiating event in colorectal carcinogenesis. There are growing evidences suggest that traditional herbal plant medicines are being raised as a complementary alternative treatment for cancer. In this series, Butea (B) monosperma has been illustrated as a valuable traditional medicinal plant with >45 medicinal traits. Therefore, by targets this pathway using n-butanol fraction of B. monosperma flower extract (NBF-BMFE) could be a better therapeutic strategy for treating CRC. In this present study, we evaluate the inhibitory effect of NBF-BMFE against over activated Wnt signaling mediated colon cancer cells (SW480). Interestingly, the in vitro finding described that the NBF-BMFE had good antiproliferative effect against SW480 human colon cancer cells. Moreover, it showed significant level of down regulated expression in Wnt signaling proteins such as β-catenin, adenomatous polyposis coli (APC), glycogen synthase kinase 3β (GSK-3β), cyclin D1 and c-myc in time-dependent manner. Further, the in silico results of NBF-BMFE derived compounds have shown good binding interaction with target sites of β-catenin, APC and GSK-3β protein. In conclusion, NBF-BMFE may be used as an effective inhibitor for Wnt signaling targeted combined chemotherapeutic agents against CRC.

The Role of Yoga in the Complementary Treatment of Cancer

The Role of Yoga in the Complementary Treatment of Cancer

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review.

Recurrent cervical cancer is a clinically complex disease that is difficult to treat. There are numerous treatment options, but the results achieved by each are poor. External-beam radiation therapy of the pelvic lymph drainage area, in combination with intracavitary afterloading or the interstitial implantation of a radiation source (i.e., brachytherapy), are the current standard radiotherapy regimens used in high-risk clinical targets. However, there are few reports concerning the use of iodine-125 (125I) seed implantation brachytherapy in recurrent cervical cancer, and the effects of treatment and adverse reactions have not yet been systematically evaluated. In the present study one such case is reported, in which the patient was successfully treated with intensity-modulated radiotherapy (IMRT) in combination with 125I seed implantation. The patient, a 47-year-old woman, was initially diagnosed with International Federation of Gynecology and Obstetrics stage IB1 cervical cancer, and received a radical hysterectomy, left lateral adnexectomy and pelvic lymph node dissection. A follow-up examination 23 months later revealed vaginal invasion and a solitary lump in the cervical stump with a maximum diameter of 38 mm. The patient was subsequently diagnosed with recurrent cervical cancer and was treated with six cycles of docetaxel and nedaplatin chemotherapy, alongside IMRT and interstitial 125I seed implantation. At the point of manuscript submission, the patient's progression-free survival time was 33 months and long-term adverse reactions were acceptable. The response of this patient indicates that 125I seed implantation could be used as a complementary treatment for recurrent cervical cancer and may also prove to be a reliable means for the comprehensive treatment of primary cervical cancer, as the patient had characteristics similar to primary cervical cancer, although this hypothesis could not be confirmed in the present study.

ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs

BackgroundOsteosarcoma is the most common bone tumor and is associated with a poor prognosis. Conventional therapies, surgery and chemotherapy, are still the standard but soon reach their limits. New therapeutic approaches are therefore needed. Conventional aqueous mistletoe extracts from the European mistletoe (Viscum album L.) are used in complementary cancer treatment. These commercial extracts are water-based and do not include water-insoluble compounds such as triterpenic acids. However, both hydrophilic and hydrophobic triterpenic acids possess anti-cancer properties. In this study, a whole mistletoe extract viscumTT re-created by combining an aqueous extract (viscum) and a triterpene extract (TT) was tested for its anti-cancer potential in osteosarcoma.MethodsTwo osteosarcoma cell lines were treated with three different mistletoe extracts viscum, TT and viscumTT to compare their apoptotic potential. For this purpose, annexin/PI staining and caspase-3, −8 and −9 activity were investigated by flow cytometry. To determine the mechanism of action, alterations in expression of inhibitors of apoptosis (IAPs) were detected by western blot. Apoptosis induction by co-treatment of viscum, TT and viscumTT with doxorubicin, etoposide and ifosfamide was examined by flow cytometry.ResultsIn vitro as well as ex vivo, the whole mistletoe extract viscumTT led to strong inhibition of proliferation and synergistic apoptosis induction in osteosarcoma cells. In the investigations of mechanism of action, inhibitors of apoptosis such as XIAP, BIRC5 and CLSPN showed a clear down-regulation after viscumTT treatment. In addition, co-treatment with doxorubicin, etoposide and ifosfamide further enhanced apoptosis induction, also synergistically.ConclusionViscumTT treatment results in synergistic apoptosis induction in osteosarcoma cells in vitro and ex vivo. Additionally, conventional standard chemotherapeutic drugs such as doxorubicin, etoposide and ifosfamide were able to dramatically enhance apoptosis induction. These results promise a high potential of viscumTT as an additional adjuvant therapy approach for osteosarcoma.

Perception of risk and communication among conventional and complementary health care providers involving cancer patients’ use of complementary therapies: a literature review

BackgroundCommunication between different health care providers (conventional and complementary) and cancer patients about their use of complementary therapies affects the health and safety of the patients. The aim of this study was to examine the qualitative research literature on the perception of and communication about the risk of complementary therapies between different health care providers and cancer patients.MethodsSystematic searches in six medical databases covering literature from 2000 to 2015 were performed. The studies were accessed according to the level of evidence and summarized into different risk situations. Qualitative content analysis was used to analyze the text data, and the codes were defined before and during the data analysis.ResultsTwenty-nine papers were included in the primary analysis and five main themes were identified and discussed. The main risk situations identified were 1. Differences in treatment concepts and philosophical values among complementary and conventional health care providers. 2. Adverse effects from complementary products and herbs due to their contamination/toxicity and interactions with conventional cancer treatment. 3. Health care physicians and oncologists find it difficult to recommend many complementary modalities due to the lack of scientific evidence for their effect. 4. Lack of knowledge and information about complementary and conventional cancer treatments among different health care providers.ConclusionThe risk of consuming herbs and products containing high level of toxins is a considerable threat to patient safety (direct risk). At the same time, the lack of scientific evidence of effect for many complementary therapies and differences in treatment philosophy among complementary and conventional health care providers potentially hinder effective communication about these threats with mutual patients (indirect risk). As such, indirect risk may pose an additional risk to patients who want to combine complementary therapies with conventional treatment in cancer care. Health care providers who care for cancer patients should be aware of these risks.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-016-1326-3) contains supplementary material, which is available to authorized users.

A Complementary Cancer Treatment Protocol

A Complementary Cancer Treatment Protocol

Fenofibrate in cancer: mechanisms involved in anticancer activity

Objective: To review the mechanisms of anti-cancer activity of fenofibrate (FF) and other Peroxisome Proliferator Activator Receptor α (PPARα) agonists based on evidences reported in the published literature.Methods: We extensively reviewed the literature concerning FF as an off target anti-cancer drug. Controversies regarding conflicting findings were also addressed.Results:The main mechanism involved in anti-cancer activity is anti-angiogenesis through down-regulation of Vascular Endothelial Growth Factor (VEGF), Vascular Endothelial Growth Factor Receptor (VEGFR) and Hypoxia Inducible factor-1 α (HIF-1α), inhibition of endothelial cell migration, up-regulation of endostatin and thrombospondin-1, but there are many other contributing mechanisms like apoptosis and cell cycle arrest, down-regulation of Nuclear Factor Kappa B (NF-kB) and Protein kinase B (Akt) and decrease of cellular energy by impairing mitochondrial function. Growth impairment is related to down-regulation of Phospho-Inositol 3 Kinase (PI3K)/Akt axis and down-regulation of the p38 map kinase (MAPK) cascade. A possible role should be assigned to FF stimulated over-expression of Tribbles Homolog-3 (TRIB3) which inhibits Akt phosphorylation. Important anti-cancer and anti-metastatic activities are due to down-regulation of MCP-1 (monocyte chemotactic protein-1), decreased Metalloprotease-9 (MMP-9) production, weak down-regulation of adhesion molecules like E selectin, intercellular adhesion molecules (ICAM) and Vascular Endothelial Adhesion Molecules (VCAM), and decreased secretion of chemokines like Interleukin-6 (IL-6), and down-regulation of cyclin D-1. There is no direct link between FF activity in lipid metabolism and anticancer activity, except for the fact that many anticancer actions are dependent from PPARα agonism. FF exhibits also PPARα independent anti-cancer activities.Conclusions: There are strong evidences indicating that FF can disrupt growth-related activities in many different cancers, due to anti-angiogenesis and anti-inflammatory effects. Therefore FF may be useful as a complementary adjunct treatment of cancer, particularly included in anti-angiogenic protocols like those currently increasingly used in glioblastoma. There are sound reasons to initiate well planned phase II clinical trials for FF as a complementary adjunct treatment of cancer.

Fenofibrate in cancer: mechanisms involved in anticancer activity

Objective: To review the mechanisms of anti-cancer activity of fenofibrate (FF) and other Peroxisome Proliferator Activator Receptor α (PPARα) agonists based on evidences reported in the published literature.Methods: We extensively reviewed the literature concerning FF as an off target anti-cancer drug. Controversies regarding conflicting findings were also addressed.Results:The main mechanism involved in anti-cancer activity is anti-angiogenesis through down-regulation of Vascular Endothelial Growth Factor (VEGF), Vascular Endothelial Growth Factor Receptor (VEGFR) and Hypoxia Inducible factor-1 α (HIF-1α), inhibition of endothelial cell migration, up-regulation of endostatin and thrombospondin-1, but there are many other contributing mechanisms like apoptosis and cell cycle arrest, down-regulation of Nuclear Factor Kappa B (NF-kB) and Protein kinase B (Akt) and decrease of cellular energy by impairing mitochondrial function. Growth impairment is related to down-regulation of Phospho-Inositol 3 Kinase (PI3K)/Akt axis and down-regulation of the p38 map kinase (MAPK) cascade. A possible role should be assigned to FF stimulated over-expression of Tribbles Homolog-3 (TRIB3) which inhibits Akt phosphorylation. Important anti-cancer and anti-metastatic activities are due to down-regulation of MCP-1 (monocyte chemotactic protein-1), decreased Metalloprotease-9 (MMP-9) production, weak down-regulation of adhesion molecules like E selectin, intercellular adhesion molecules (ICAM) and Vascular Endothelial Adhesion Molecules (VCAM), and decreased secretion of chemokines like Interleukin-6 (IL-6), and down-regulation of cyclin D-1. There is no direct link between FF activity in lipid metabolism and anticancer activity, except for the fact that many anticancer actions are dependent from PPARα agonism. FF exhibits also PPARα independent anti-cancer activities.Conclusions: There are strong evidences indicating that FF can disrupt growth-related activities in many different cancers, due to anti-angiogenesis and anti-inflammatory effects. Therefore FF may be useful as a complementary adjunct treatment of cancer, particularly included in anti-angiogenic protocols like those currently increasingly used in glioblastoma. There are sound reasons to initiate well planned phase II clinical trials for FF as a complementary adjunct treatment of cancer.

Development of a standardized and effect-optimized herbal extract of Wedelia chinensis for prostate cancer

Herbal medicine is a popular complementary or alternative treatment for prostate cancer. Wedelia chinensis has at least three active compounds, wedelolactone, luteolin, and apigenin synergistically inhibiting prostate cancer cell growth in vitro. Here, we report a systematic study to develop a standardized and effect-optimized herbal extract, designated as W. chinensis extract (WCE) to facilitate its future scientific validation and clinical use. Ethanolic extract of dried W. chinensis plant was further condensed, acid hydrolyzed, and enriched with preparative chromatography. The chemical compositions of multiple batches of the standardized preparation WCE were quantified by LC/MS/MS, and biological activities were analyzed by in vitro and in vivo assays. Furthermore, the pharmacokinetics of the holistic WCE were compared with the combination of the equivalent principal active compounds through oral administration. The results indicated that quantitative chemical assay and PSA (prostate-specific antigen)-reporter assay together are suitable to measure the quality and efficacy of a standardized Wedelia extract on a xenograft tumor model. The presence of minor concomitant compounds in WCE prolonged the systemic exposure to the active compounds, thus augmented the anti-tumor efficacy of WCE. In conclusion, a combination of LC/MS/MS and PSA reporter assay is suitable to qualify a standardized preparation of WCE. Furthermore, the pharmacokinetics and oral bioavailability of active compounds demonstrate that holistic WCE exerted additional pharmacological synergy beyond the multi-targeted therapeutic effects caused by more than one active compound. WCE merits a higher priority to be studied for use in prostate cancer treatment.

Mathematical analysis and classification of tumor immune dynamics in T cell transfer treatment

Immunotherapy for cancer is a forthcoming therapeutic option in cancer treatment. A variety of approaches, including adoptive cell transfer, adjuvant therapy, and monoclonal antibody therapy, are currently used as complementary or alternative cancer treatments. Since immunity against tumors is established as a result of complex interactions among tumors and immune cells, a theoretical framework to elucidate the dynamics of tumor killing by immune cells initiated by clinical intervention needs to be developed. We construct a simple mathematical model that describes the killing of tumors by T cells. We focus on a mathematical characterization of the effect of adoptive cell transfer therapy, the injection of a patient's own ex vivo activated T cells to initiate tumor immunity. On the basis of rigorous mathematical analyses and numerical computations, we provide biological interpretations for the possible outcomes of adoptive cell transfer under three different scenarios in terms of proliferation. In our modeling framework, adoptive cell transfer therapy can be understood as a driving force that potentially operates to shift the state of an immune response from inactive to active. On the other hand, our modeling framework suggests the possibility that a tumor can exploit a self-augmenting proliferation of T cells mediated by autocrine/paracrine signaling as an escape strategy from an immune response.

Immunomodulatory activity of Dioscorea membranacea Pierre rhizomes and of its main active constituent Dioscorealide B

BackgroundThe rhizomes of Dioscorea membranacea Pierre, also called Hua-Khao-Yen by Thai name, are used as ingredients in many Thai traditional medicines for the alternative or complementary treatment of cancer and AIDs. Preliminary in vitro studies have indicated that D. membranacea extracts exhibited high cytotoxic activity with several cancer cell lines, but the underlining mechanisms are far from clear. The aims of this study were to investigate the effects of ethanolic and aqueous crude extracts from D. membranacea Pierre, and pure compound from D. membranacea Pierre, Dioscorealide B, on natural killer cells activity and on lymphocyte proliferation.MethodsImmunomodulatory activity was investigated using PBMCs from healthy donors. NK cells activity was performed by the chromium release assay using PBMCs as effector cells, and K562 cells line labelled with chromium as target cells. Lymphocyte proliferation was determined by 3H-thymidine uptake. The degree of activation was expressed as the stimulation index.ResultsThe crude ethanolic extracts of D. membranacea Pierre significantly stimulated NK cells activity against K562 cells line at lower concentrations of 10 and 100 ng/ml, but not at higher concentrations. The ethanolic extracts showed no observable effect on lymphocyte proliferation. The crude water extracts significantly increased NK cell activity at concentrations of 10 ng/ml, 100 ng/ml, 1 μg/ml, 10 μg/ml and 100 μg/ml, and also activated lymphocyte proliferation at concentration of 1 ng/ml, 10 ng/ml, 100 ng/ml, 1 μg/ml, 5 μg/ml, 10 μg/ml and 100 μg/ml. However, Dioscorealide B had no significant effect at lower concentrations (0–1 μg/ml and 0–0.1 μg/ml, respectively) on NK cell activity and lymphocyte proliferation. In fact higher concentrations (>10 μg/ml and >0.5 μg/ml) of Dioscorealide B cause a significant decrease in NK cell activity and lymphocyte proliferation.ConclusionsD. membranacea Pierre stimulated NK cells activity and lymphocyte proliferation, but Dioscorealide B either had no effect, and at higher concentrations decreased NK cell activity and lymphocyte proliferation. Our results suggest that both extracts of D. membranacea Pierre significantly increases immune function, but the underlining mechanism is not clearly understood.

Video endoscopic inguinal lymphadenectomy: Surgical and oncological results

IntroductionWe evaluated the reproducibility of video endoscopic inguinal lymphadenectomy (VEIL) and we report our initial experience in the treatment of penile cancer with palpable inguinal lymph nodes. Materials and methodsFrom July 2006 to November 2010 were conducted 33 VEIL in 20 patients as complementary treatment for penile cancer in two referral hospitals in Latin America. We analyzed the epidemiological and clinical characteristics of patients and surgical and oncologic outcomes. ResultsFifty-five percent of the patients included were clinical stage N0 and 45% were N+. Thirteen patients underwent bilateral VEIL and the remaining seven underwent VEIL unilateral and conventional open surgery in the contralateral limb. The average operative time for VEIL was 119min and mean resected lymph nodes was 8 per lymphadenectomy. The overall complication rate was 33.2%. No patient had skin necrosis. The lymphatic complication rate was 27.2%. Of the 6 cases in which the saphenous vein was preserved (18.2%) there were no lymphatic complications (p=.2). The overall survival rate was 80% and cancer-specific survival was 90%. Mean follow-up was 20 months. ConclusionsVEIL in the adjunctive treatment of penile cancer is safe, reproducible and may be an alternative to conventional lymphadenectomy. Patients with palpable lymphadenopathy also may benefit from this technique. Oncological results seem to be adequate however require longer follow-up to be confirmed.

Yoga as an Alternative and Complementary Treatment for Cancer: A Systematic Review

Cancer is an important public health concern, with millions of patients affected worldwide. Given the physical, psychological, and physiologic changes associated with cancer, holistic therapies are needed to treat all aspect of the disease. A systematic review was conducted to determine the efficacy of yoga as a treatment option for cancer since 2010. Included studies were published from January 2010 to July 2012 and were indexed in MEDLINE, CINAHL, and Alt HealthWatch. Thirteen studies met the inclusion criteria. Eight of these studies were performed in the United States, and one each was conducted in Slovenia, Italy, the United Kingdom, Canada, and Turkey. The evidence for efficacy of yoga as an alternative and complementary treatment for cancer is mixed, although generally positive. Limitations of the reviewed interventions included a mixed use of instruments, weak quantitative designs, small sample sizes, and a lack of theory-based studies.

Linfadenectomía inguinal vídeo endoscópica: resultados quirúrgicos y oncológicos

IntroductionWe evaluated the reproducibility of video endoscopic inguinal lymphadenectomy (VEIL) and we report our initial experience in the treatment of penile cancer with palpable inguinal lymph nodes. Material and methodsFrom July 2006 to November 2010 were conducted 33 VEIL in 20 patients as complementary treatment for penile cancer in two referral hospitals in Latin America. We analyzed the epidemiological and clinical characteristics of patients and surgical and oncologic outcomes. ResultsFifty-five percent of the patients included were clinical stage N0 and 45% were N +. Thirteen patients underwent bilateral VEIL and the remaining seven underwent VEIL unilateral and conventional open surgery in the contralateral limb. The average operative time for VEIL was 119minutes and mean resected lymph nodes was 8 per lymphadenectomy. The overall complication rate was 33.2%. No patient had skin necrosis. The lymphatic complication rate was 27.2%. Of the 6 cases in which the saphenous vein was preserved (18.2%) there were no lymphatic complications (P=,2). The overall survival rate was 80% and cancer-specific survival was 90%. Mean follow-up was 20 months. ConclusionsVEIL in the adjunctive treatment of penile cancer is safe, reproducible and may be an alternative to conventional lymphadenectomy. Patients with palpable lymphadenopathy also may benefit from this technique. Oncological results seem to be adequate however require longer follow-up to be confirmed.

A comparison of decision-making processes for conventional and complementary medicine in cancer patients

To understand the decision-making processes involved in conventional medicine and complementary medicine cancer treatment, and the role that information plays, a cross-sectional survey of cancer patients was carried out at 2 Australian cancer centres. Data was obtained from 75 cancer patients. When asked about complementary medicine use, 36 (48%) patients reported using some form of complementary medicine in conjunction with their conventional treatment. In terms of decision-making, our findings suggest that although cancer patients appear to be at different stages of decision-making for complementary medicine compared with conventional medicine, there was no difference between the decision-making process for cancer patients when it comes to utilising conventional medicine or complementary medicine: patients reported comparable high decisional self-efficacy and low decisional conflict for both areas of medicine.